Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-02 pm EST
47.34 USD   +4.64%
01/18Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Price Target
MT
01/10Transcript : Ultragenyx Pharmaceutical Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM
CI
01/09Ultragenyx reports preliminary 2022 revenue guidance for 2023 revenue and cash usage pipeline updates and 2023 milestones
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx to Present at Piper Sandler Healthcare Conference

11/22/2022 | 04:02pm EST

NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Piper Sandler Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:00 AM ET in New York.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 120 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Joshua Higa 
ir@ultragenyx.com  

Media  
Jeff Blake 
415-612-7784 
media@ultragenyx.com  


Primary Logo


ę GlobeNewswire 2022
All news about ULTRAGENYX PHARMACEUTICAL INC.
01/18Canaccord Genuity Assumes Coverage on Ultragenyx Pharmaceutical With Buy Rating, $90 Pr..
MT
01/10Transcript : Ultragenyx Pharmaceutical Inc. Presents at 41st Annual J.P. Morg..
CI
01/09Ultragenyx reports preliminary 2022 revenue guidance for 2023 revenue and cash usage pi..
AQ
01/06Ultragenyx Pharmaceutical Reports Preliminary 2022 Revenue, Issues 2023 Guidance
MT
01/06Ultragenyx Pharmaceutical Inc. : Results of Operations and Financial Condition, Regulation..
AQ
01/06Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; ..
GL
01/06Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; ..
AQ
01/06Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023
CI
01/04Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
2022HC Wainwright Assumes Ultragenyx With Buy Rating, $82 Price Target
MT
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 362 M - -
Net income 2022 -709 M - -
Net cash 2022 750 M - -
P/E ratio 2022 -4,72x
Yield 2022 -
Capitalization 3 319 M 3 319 M -
EV / Sales 2022 7,10x
EV / Sales 2023 6,90x
Nbr of Employees 1 119
Free-Float 95,1%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 47,34 $
Average target price 91,37 $
Spread / Average Target 93,0%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Office
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.2.18%3 319
VERTEX PHARMACEUTICALS9.87%81 440
REGENERON PHARMACEUTICALS, INC.4.12%80 956
WUXI APPTEC CO., LTD.17.28%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436